Melanoma Clinical Trials in Austin

Showing 81-100 of 114 trials

Multimodal Spectroscopy (MMS) for in Vivo Noninvasive Assessment of Skin

NCT02704039

The goal of this research program is to develop a simple, noninvasive diagnostic device for assessing skin pathology without the need for a biopsy. The device being studied is a single system capable of collecting three spectroscopy measurements (Raman, diffuse reflectance and laser induced fluorescence spectroscopy) from skin lesion sites. In order to accomplish this objective, the investigators propose to: 1) develop biophysical model for Raman spectroscopy of skin cancers, 2) conduct a clinical pilot study to collect MMS data from a minimum of 250 patients to determine the diagnostic accuracy (sensitivity and specificity) of MMS for diagnosing skin malignancy.

Skin Cancer

University of Texas at Austin239 participantsStarted Jan 2016

Austin, Texas, United States

COMPLETEDPHASE174 miles

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

NCT01307267

A study of PF-05082566, a 4-1BB agonist monoclonal antibody (mAb), in patients with solid tumors or b-cell lymphomas, and in combination with rituximab in patients with CD20 positive Non-Hodgkin's Lymphoma (NHL).

Lymphoma, Non-HodgkinLymphoma, FollicularLymphoma, Large B-Cell, Diffuse+4 more

Pfizer190 participantsStarted Jun 2011

Duarte, California, United States • La Jolla, California, United States • La Jolla, California, United States +39 more locations

Multimodal Spectroscopy (MMS) for in Vivo Noninvasive Assessment of Skin

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

Melanoma Trials in Other Cities

Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma

Phase II, 2nd Line Melanoma - RAND Monotherapy

A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

Vaccine Therapy in Treating Patients With Malignant Melanoma

Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec

A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma

STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma

A Study of Tasisulam in Treating Participants With Malignant Melanoma

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma

Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung

Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)

Other Conditions in Austin